Regimen Optimization Study

Calcineurin inhibitor (CNI)

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Men and women, aged 18 to 75

- Serologic test results are positive for past exposure to Epstein Barr Virus (EBV+)

- Diagnosed with end stage renal disease (ESRD) and scheduled to undergo transplantation
of a non-HLA identical, living or standard criteria deceased donor kidney

Exclusion Criteria:

- Primary cause of ESRD is: primary focal segmental glomerulosclerosis; or Type I or II
membranoproliferative glomerulonephritis; or Hemolytic Uremic Syndrome / Thrombotic
Thrombocytopenic Purpura

- Had a previous graft loss due to acute rejection

- At increased immunologic risk of graft loss due to panel reactive antibodies (PRA)
>20% or need for desensitization therapy

- Scheduled to receive a: kidney from identical twin; or paired kidney; or kidney from a
Cytomegalovirus(CMV) positive donor when recipient is CMV negative; or kidney from an
extended criteria donor

- Have a body mass index (BMI) of > 35 kg/m2 for nondiabetics or > 30 kg/m2 for
diabetics

- Diagnosed as Hepatitis B positive; or Hepatitis C positive; or HIV positive; or
currently or previously active or inadequately treated latent